ArticleScientific reports2026
Isolation and characterization of lytic bacteriophages with therapeutic potential against multidrug resistant Klebsiella pneumoniae from Ethiopia.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genome sequences of four virulentMicrobiology resource announcements · 2026Article
- Antibacterial Immunotherapy: Mechanistic Insights, Emerging Therapeutic Strategies, and Clinical Translation.Infection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klebsiella pneumoniae is a common pathogen responsible for various infections, with multidrug-resistant (MDR) strains increasingly complicating treatment. Phage therapy has shown significant potential in treating difficult bacterial infections; however, research specifically focused on phages targeting this bacterium remains limited. This study aimed to isolate and characterize lytic bacteriophages that target multidrug-resistant K. pneumoniae. Phages were isolated from 66 environmental samples through spot assays conducted on 10 multidrug-resistant strains. Phages were isolated via spot assays and purified via streak plating. Characterization included PCR-based identification and classification, determination of the latent period, efficiency of plating, burst size, stability testing, and evaluation of in vitro bactericidal activity. From a total of 660 spots tested against 10 multidrug-resistant (MDR) isolates, 102 phages were successfully isolated. These phages demonstrated individual lytic activity ranging from 8% (4/46) to 63% (29/46). PCR-based classification of the 60 bacteriophages identified six distinct virulent phage genera, with Taipeivirus being the most prevalent at 18.3% (11/60) and Webervirus the least common at 10.0% (6 out of 60). Stability assessments of pH and temperature demonstrated optimal activity between pH 5 and 9 and at temperatures up to 50 °C. These results endorse phage therapy as a viable alternative for treating MDR and hypervirulent K. pneumoniae infections. The data offer critical insights into local bacteriophage diversity and underscore its potential for developing targeted therapeutic agents. Genome sequencing, in vivo studies, and clinical trials are required to validate the efficacy and safety of these phages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.